Wells Fargo & Company Forecasts Strong Price Appreciation for Mesa Laboratories (NASDAQ:MLAB) Stock

Mesa Laboratories (NASDAQ:MLAB) had its price objective lifted by Wells Fargo & Company from $83.00 to $94.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has an “equal weight” rating on the medical instruments supplier’s stock. Wells Fargo & Company‘s target price would indicate a potential upside of 3.07% from the company’s previous close.

Several other equities research analysts also recently commented on MLAB. Wall Street Zen raised shares of Mesa Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Weiss Ratings reiterated a “sell (d)” rating on shares of Mesa Laboratories in a research note on Thursday, January 22nd. Finally, Zacks Research raised Mesa Laboratories from a “strong sell” rating to a “hold” rating in a report on Friday, January 9th. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Reduce” and an average target price of $94.00.

Mesa Laboratories Trading Down 0.4%

NASDAQ MLAB opened at $91.20 on Wednesday. The company has a quick ratio of 1.44, a current ratio of 1.94 and a debt-to-equity ratio of 0.86. Mesa Laboratories has a 52 week low of $55.45 and a 52 week high of $155.12. The business has a 50 day moving average price of $81.85 and a 200-day moving average price of $74.72. The company has a market cap of $503.42 million, a price-to-earnings ratio of 142.50 and a beta of 0.89.

Mesa Laboratories (NASDAQ:MLAB) last posted its quarterly earnings results on Tuesday, February 3rd. The medical instruments supplier reported $3.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.41 by $0.66. Mesa Laboratories had a net margin of 1.51% and a return on equity of 22.02%. The business had revenue of $65.13 million during the quarter, compared to the consensus estimate of $63.23 million. As a group, equities analysts expect that Mesa Laboratories will post 8 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of MLAB. Farther Finance Advisors LLC increased its position in shares of Mesa Laboratories by 17,733.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 535 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 532 shares during the last quarter. CWM LLC grew its position in Mesa Laboratories by 48.9% during the third quarter. CWM LLC now owns 597 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 196 shares during the period. BNP Paribas Financial Markets increased its holdings in Mesa Laboratories by 115.3% during the second quarter. BNP Paribas Financial Markets now owns 786 shares of the medical instruments supplier’s stock worth $74,000 after buying an additional 421 shares during the last quarter. Tower Research Capital LLC TRC raised its position in Mesa Laboratories by 432.9% in the second quarter. Tower Research Capital LLC TRC now owns 842 shares of the medical instruments supplier’s stock worth $79,000 after acquiring an additional 684 shares during the period. Finally, MQS Management LLC purchased a new position in Mesa Laboratories in the second quarter valued at about $207,000. Hedge funds and other institutional investors own 90.60% of the company’s stock.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.